Royalty Pharma plc Business Combination, Acquisition Related Costs
Royalty Pharma plc (RPRX) reported Business Combination, Acquisition Related Costs of $28.90 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-08-05
- Royalty Pharma plc business combination, acquisition related costs for the quarter ending 2025-12-31 was -$700.00K.
- Royalty Pharma plc business combination, acquisition related costs for the quarter ending 2025-09-30 was $1.00M.
- Royalty Pharma plc business combination, acquisition related costs for the quarter ending 2025-06-30 was $15.00M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$700.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-05 | $300.00K derived: sum of 2 quarters · filed 2026-08-05 | $15.30M derived: sum of 3 quarters · filed 2026-08-05 | $28.90M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-05 | $16.00M derived: sum of 2 quarters · filed 2025-11-05 | $29.60M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $15.00M 10-Q · filed 2025-08-06 | $28.70M 10-Q · filed 2025-08-06 | ||
| 2024-09-30 | $29.60M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |